Cite
HARVARD Citation
Stefanini, B. et al. (2022). Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors. Digestive and liver disease. 54 (11), pp. 1563-1572. [Online].